Imaging NRF2 Activation in Lung Cancer
Author Information
Author(s): Hannah E. Greenwood, Abigail R. Barber, Richard S. Edwards, Will E. Tyrrell, Madeleine E. George, Sofia N. dos Santos, Friedrich Baark, Muhammet Tanc, Eman Khalil, Aimee Falzone, Nathan P. Ward, Janine M. DeBlasi, Laura Torrente, Pritin N. Soni, David R. Pearce, George Firth, Lydia M. Smith, Oskar Vilhelmsson Timmermand, Ariana Huebner, Charles Swanton, Robert E. Hynds, Gina M. DeNicola, Timothy H. Witney
Primary Institution: King’s College London
Hypothesis
Can positron emission tomography imaging with [18F]FSPG non-invasively identify NRF2 activation in non-small cell lung cancer?
Conclusion
[18F]FSPG is a predictive marker of therapy resistance in non-small cell lung cancer and can be used for patient selection in clinical evaluations.
Supporting Evidence
- NRF2 activation is linked to poor outcomes in non-small cell lung cancer.
- Positron emission tomography imaging with [18F]FSPG can detect NRF2 activation.
- System xc− is a metabolic vulnerability that can be targeted therapeutically.
- NRF2-related gene expression signatures were identified in a large cohort of NSCLC patients.
- NRF2-high tumors showed significantly higher [18F]FSPG retention compared to NRF2-low tumors.
Takeaway
Scientists found a way to see if a cancer-related protein called NRF2 is active in lung cancer using a special imaging technique. This could help doctors choose the right treatment for patients.
Methodology
The study used positron emission tomography imaging with the radiotracer [18F]FSPG in various models of non-small cell lung cancer to assess NRF2 activation.
Potential Biases
Potential bias in patient selection and model representation.
Limitations
The study's findings may not be generalizable to all patients with non-small cell lung cancer due to the specific models used.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website